Delcath Systems

Delcath Systems, Inc. is a United States-based specialty pharmaceutical and medical-device company focused on interventional oncology. Its principal technology is percutaneous hepatic perfusion, commonly abbreviated PHP, a procedure intended to deliver a high concentration of chemotherapy directly to the liver while isolating the organ from the systemic circulation during treatment. The company’s technology is designed for patients with liver-dominant or liver-confined malignancies, including metastatic uveal melanoma and other primary or metastatic liver tumors. The company was founded in 1988 and is headquartered in Queensbury, New York. Its business combines medical-device engineering, pharmaceutical delivery, clinical development, regulatory work, and commercialization. Rather than administering chemotherapy only through conventional intravenous or oral routes, Delcath’s approach uses catheter-based vascular isolation and extracorporeal filtration. In the PHP procedure, catheters are placed in the hepatic and caval circulation, the liver is temporarily isolated, and a chemotherapeutic agent is circulated through the organ. The treated blood is then filtered before being returned to the patient. The objective is to expose tumors in the liver to a locally concentrated dose while reducing systemic exposure relative to an unisolated infusion. Delcath’s principal commercial offering is the Hepzato Kit, also known in the company’s earlier development work as the Delcath System or a PHP system. The system is associated with melphalan, an established chemotherapy drug, and is intended for use in a specialized hospital procedure conducted by trained interventional oncology and multidisciplinary teams. The product’s development has centered particularly on unresectable hepatic metastases from uveal melanoma, a rare eye cancer that can spread to the liver. The company has also investigated PHP for primary liver cancer and hepatic metastases arising from neuroendocrine cancers, adenocarcinomas, and other malignancies. Delcath’s development history includes clinical studies in the United States and collaboration with major cancer centers. The company entered into a Cooperative Research and Development Agreement with the National Cancer Institute and received regulatory development designations, including Fast Track status and a Special Protocol Assessment, for melphalan-based treatment of unresectable liver tumors. These milestones reflected an effort to establish PHP as a treatment option for patients whose disease was not readily manageable through surgery, systemic therapy, or other liver-directed interventions. The business operates in a specialized and technically demanding segment. Adoption depends on clinical evidence, regulatory authorization, reimbursement, hospital investment, physician training, procedure capacity, and patient selection. Its addressable market is therefore narrower than that of conventional pharmaceutical companies, but the company’s strategy is centered on diseases with substantial unmet need and limited treatment alternatives. Delcath has also built an intellectual-property portfolio around its perfusion and filtration technologies. Delcath is publicly traded on the Nasdaq under the symbol DCTH. Its current corporate identity is closely tied to the commercialization and further development of Hepzato and to expanding the potential use of regional hepatic perfusion. Publicly available reference material describes the company as active in the United States; detailed information about broader international commercial operations, current management, ownership, and financial performance is not established in the supplied sources.

Delcath Systems was established in 1988 as a medical-technology company pursuing a regional approach to chemotherapy administration. Its long-term development concept was to treat tumors within a specific organ, particularly the liver, with a high local concentration of chemotherapy while limiting the amount of drug circulating through the rest of the body. This approach led to the development of percutaneous hepatic perfusion, or PHP. The PHP platform uses interventional radiology techniques to isolate the liver’s blood supply and drainage temporarily. A chemotherapeutic agent is circulated through the liver, after which the blood is directed through an extracorporeal filtration circuit before returning to the patient. The procedure was designed for cancers that are difficult to remove surgically or that remain concentrated in the liver. Melphalan became the principal drug associated with Delcath’s development program because of its activity against certain malignancies and its use in the company’s liver-directed treatment strategy. During its clinical-development period, Delcath studied the technology in metastatic melanoma involving the liver, including metastatic uveal melanoma, as well as primary liver cancer and liver metastases originating from neuroendocrine tumors, adenocarcinomas, and other cancers. The company’s work included a Phase III melanoma study and collaborations with a network of major academic and cancer-treatment centers. Listed institutions included the University of Pittsburgh Medical Center, the National Cancer Institute, Albany Medical Center, John Wayne Cancer Center, Moffitt Cancer Center, Morristown Memorial Hospital, Providence Cancer Center, St. Luke’s Cancer Center, Swedish Medical Center, the University of Maryland Medical Center, and the University of Texas Medical Branch. Delcath also entered into a Cooperative Research and Development Agreement with the National Cancer Institute. Its regulatory-development history included Fast Track designation and a Special Protocol Assessment from the United States Food and Drug Administration for the use of melphalan in unresectable liver tumors. These interactions were important because PHP required evaluation not only as a drug treatment but also as a complex combination of a chemotherapeutic agent, vascular-access procedure, perfusion equipment, and filtration system. The company’s technology was initially referred to in development materials as the Delcath System and as a PHP system. Its later commercial identity became associated with the Hepzato Kit. The product is intended for use in specialist hospitals by teams capable of performing advanced catheter-based procedures and managing the associated anesthesia, vascular, chemotherapy, and filtration requirements. The commercial model consequently depends on training, institutional readiness, reimbursement, and the availability of appropriate patients in addition to the product’s regulatory status. Delcath is headquartered in Queensbury, New York, and is publicly traded on Nasdaq under the ticker DCTH. Its intellectual-property portfolio has been described in reference material as including patents in multiple jurisdictions. The company’s present strategic focus is the commercialization and further development of regional hepatic perfusion for selected liver cancers. Because the supplied historical sources provide limited information about later corporate leadership, international expansion, financial performance, and operating changes, those areas remain unspecified rather than inferred.

• 1988

  Company founded

  [1]Delcath Systemsen.wikipedia.org

  Delcath Systems was established as a company focused on medical technologies for regional cancer treatment.

• Development of the Delcath System

  [1]Delcath Systemsen.wikipedia.org

  The company developed a percutaneous hepatic perfusion platform combining hepatic vascular isolation, regional melphalan delivery, and extracorporeal filtration.

• National Cancer Institute collaboration

  [1]Delcath Systemsen.wikipedia.org

  Delcath entered a Cooperative Research and Development Agreement with the National Cancer Institute to support development of its liver-directed perfusion technology.

• Regulatory development designations

  [1]Delcath Systemsen.wikipedia.org

  The company received Fast Track status and a Special Protocol Assessment from the United States Food and Drug Administration for melphalan-based treatment of unresectable liver tumors.

• Phase III melanoma clinical program

  [1]Delcath Systemsen.wikipedia.org

  Delcath conducted a Phase III clinical program evaluating hepatic perfusion for melanoma involving the liver at a network of major oncology centers.

• Hepzato Kit commercial focus

  [2]Delcath Systems official websitedelcath.com

  Hepzato Kit became the company’s principal commercial product associated with melphalan-based percutaneous hepatic perfusion for selected metastatic uveal melanoma patients.

A specialized interventional-oncology company seeking to improve treatment of liver-dominant cancers through regional, high-dose chemotherapy delivery and extracorporeal blood filtration.

• Interventional oncology device and drug-delivery kit

  Hepzato Kit

  Hepzato Kit is Delcath’s principal commercial offering and is associated with the company’s percutaneous hepatic perfusion approach. The system is used as part of a specialist catheter-based procedure in which melphalan is delivered to the liver under conditions of temporary vascular isolation, followed by extracorporeal filtration of the treated blood. Its target population centers on selected patients with unresectable liver metastases from uveal melanoma. Use requires an appropriately equipped clinical setting and a trained multidisciplinary team.

• Percutaneous hepatic perfusion system

  Delcath System

  The Delcath System is the earlier or broader name used for Delcath’s PHP technology. It is designed to deliver a high concentration of chemotherapy directly through the liver while routing blood through an external filtration circuit before systemic recirculation. The development program evaluated potential use in metastatic melanoma, primary liver cancer, neuroendocrine-cancer metastases, adenocarcinoma metastases, and other hepatic malignancies.

• Focus on regional treatment for liver-dominant cancersStrategy

  Background

  Delcath concentrated its corporate and clinical-development efforts on cancers that are unresectable or predominantly located in the liver, where conventional systemic treatment may provide limited local control.

  Action taken

  The company developed PHP as a combined procedure, device, filtration system, and melphalan-delivery platform, and pursued clinical and regulatory development in metastatic uveal melanoma and other hepatic malignancies.

  Aftermath

  This strategy led to Hepzato Kit becoming the company’s principal commercial offering and kept Delcath positioned within the specialized interventional-oncology market.

  Source

• Commercialization of Hepzato KitProduct launch

  Background

  After years of development of the Delcath System and PHP procedure, the company moved toward a named commercial product centered on melphalan-based hepatic perfusion.

  Action taken

  Delcath positioned Hepzato Kit as its principal commercial product for use in specialist treatment of selected liver metastases from uveal melanoma.

  Aftermath

  The company’s identity became increasingly tied to commercial adoption, physician training, hospital readiness, reimbursement, and continued evidence generation for the PHP approach.

  Source

1. 1Delcath Systemsen.wikipedia.org
2. 2Delcath Systems official websitedelcath.com